» Articles » PMID: 10457363

Role and Interaction of Connective Tissue Growth Factor with Transforming Growth Factor-beta in Persistent Fibrosis: A Mouse Fibrosis Model

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 1999 Aug 24
PMID 10457363
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

Skin fibrotic disorders are understood to develop under the influence of some growth factors, such as transforming growth factor-beta (TGF-beta), basic fibroblast growth factor (bFGF), or connective tissue growth factor (CTGF). To establish an appropriate animal model of skin fibrosis by exogenous application of growth factors, we investigated the in vivo effects of growth factors by injecting TGF-beta, CTGF, and bFGF into the subcutaneous tissue of newborn mice. A single application of TGF-beta or bFGF resulted in the formation of transient granulated tissue that disappeared despite 7 days of consecutive injections. A single CTGF injection also caused slight granulation. However, injecting TGF-beta plus CTGF produced long-term fibrotic tissue, which persisted for at least 14 days. Also, fibrotic tissue was observed when CTGF was injected from 4 to 7 days after TGF-beta injections for the first 1-3 days. In situ hybridization analysis revealed the expression of CTGF mRNA in the fibroblasts at least in a few fibrotic conditions. These findings suggest that either CTGF mRNA or an application of exogenous CTGF protein is required for the development of persistent fibrosis. From our study, it appears that interaction of several growth factors is required for persistent fibrotic tissue formation, with TGF-beta causing the induction and CTGF needed for maintenance of skin fibrosis. The animal model on skin fibrosis by exogenous application of growth factors developed in this study may prove useful for future studies on fibrotic disorders.

Citing Articles

Molecular mechanisms of TGFβ-mediated EMT of retinal pigment epithelium in subretinal fibrosis of age-related macular degeneration.

Higashijima F, Hasegawa M, Yoshimoto T, Kobayashi Y, Wakuta M, Kimura K Front Ophthalmol (Lausanne). 2024; 2:1060087.

PMID: 38983569 PMC: 11182173. DOI: 10.3389/fopht.2022.1060087.


Non-Coding Ribonucleic Acids as Diagnostic and Therapeutic Targets in Cardiac Fibrosis.

Olson S, Tang W, Liu C Curr Heart Fail Rep. 2024; 21(3):262-275.

PMID: 38485860 PMC: 11090942. DOI: 10.1007/s11897-024-00653-1.


Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?.

Teisseire M, Giuliano S, Pages G Biomedicines. 2024; 12(2).

PMID: 38397987 PMC: 10886484. DOI: 10.3390/biomedicines12020385.


Molecular mechanisms of uterine incision healing and scar formation.

Sun Q, Tang L, Zhang D Eur J Med Res. 2023; 28(1):496.

PMID: 37941058 PMC: 10631001. DOI: 10.1186/s40001-023-01485-w.


Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach.

Chang J, Zou S, Xiao Y, Zhu D BMC Complement Med Ther. 2023; 23(1):352.

PMID: 37798725 PMC: 10557187. DOI: 10.1186/s12906-023-04171-w.